|Articles|September 14, 2021
Updates in the Treatment of Diffuse Large B-Cell Lymphoma
Advertisement
This article discusses the current treatment landscape and therapeutic strategies for relapse/refractory diffuse large B-cell lymphoma (R/R DLBCL), the role of CAR T-cell therapies in R/R DLBCL, and insights on new regimens and ongoing clinical trials from leading experts in hematologic malignancies.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5



































